Evidence & regulatory context
- Mechanism
- Whole heat-killed bacterial preparation acting as a TLR ligand / innate immune stimulant; no ChEMBL entity. FLAGGED: n_trials deliberately left 0. The 7 Salmonella hits are prophylactic conjugate and GMMA VACCINES (trivalent Salmonella conjugate vaccine, GVGH iNTS-GMMA, pan-Salmonella) intended to prevent invasive salmonellosis, a different product class and a different therapeutic intent from adjuvant heat-killed S. typhimurium as an immune stimulant, so they were not recorded as translation evidence.
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseRadiationC57BL/6FemaleGiven after irradiation as a mitigator rather than a pre-exposure radioprotector
Model: Radiation-induced lung injury following irradiation, with early inflammatory phase and later fibrotic phase assessed at 7 to 14 weeks
Heat-killed Salmonella typhimurium reduced lung hyperaemia and histopathological damage in the early inflammatory phase after irradiation and lowered collagen deposition in the later phase from 7 to 14 weeks. It also inhibited radiation-induced apoptosis and epithelial-mesenchymal transition in lun…
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
